{"generic":"Anti-Inhibitor Coagulant Complex","drugs":["Anti-Inhibitor Coagulant Complex","Autoplex T","Feiba NF","Feiba-VH"],"mono":{"0":{"id":"qi6s0","title":"Generic Names","mono":"Anti-Inhibitor Coagulant Complex"},"1":{"id":"qi6s1","title":"Dosing and Indications","sub":{"0":{"id":"qi6s1b4","title":"Adult Dosing","mono":"<ul><li><b>General guidelines:<\/b> Dose and duration dependent upon clinical condition and location and extent of bleeding; maximum single dose, 100 units\/kg; maximum daily dose, 200 units\/kg<\/li><li>Clinical response may not correlate with inhibitor titer; base on individual clinical response<\/li><li>Duration of therapy has extended to 72 hours; however, if bleeding is not controlled after 36 hours, treatment failure should be considered<\/li><li><b>Bleeding, Routine prophylaxis - Hereditary factor IX deficiency disease with inhibitor - Hereditary factor VIII deficiency disease with inhibitor:<\/b> 85 units\/kg IV every other day<\/li><li><b>Bleeding - Hereditary factor IX deficiency disease with inhibitor - Hereditary factor VIII deficiency disease with inhibitor:<\/b> Joint hemorrhage: 50 to 100 units\/kg IV every 12 hours until reduction in pain and in acute disability<\/li><li><b>Bleeding - Hereditary factor IX deficiency disease with inhibitor - Hereditary factor VIII deficiency disease with inhibitor:<\/b> Mucous membrane hemorrhage: 50 to 100 units\/kg IV every 6 hours for at least 1 day or until bleeding resolves<\/li><li><b>Bleeding - Hereditary factor IX deficiency disease with inhibitor - Hereditary factor VIII deficiency disease with inhibitor:<\/b> Soft tissue hemorrhage: 100 units\/kg IV every 12 hours until bleeding resolves<\/li><li><b>Bleeding - Hereditary factor IX deficiency disease with inhibitor - Hereditary factor VIII deficiency disease with inhibitor:<\/b> Severe hemorrhage (eg, CNS bleeding): 100 units\/kg IV every 6 to 12 hours until bleeding resolves<\/li><li><b>Bleeding - Hereditary factor IX deficiency disease with inhibitor - Hereditary factor VIII deficiency disease with inhibitor - Surgical procedure:<\/b> Preoperative dose: 50 to 100 units\/kg IV immediately before surgery<\/li><li><b>Bleeding - Hereditary factor IX deficiency disease with inhibitor - Hereditary factor VIII deficiency disease with inhibitor - Surgical procedure:<\/b> Postoperative dose: 50 to 100 units\/kg IV every 6 to 12 hours until bleeding resolves and healing is achieved<\/li><\/ul>"},"1":{"id":"qi6s1b5","title":"Pediatric Dosing","mono":"<ul><li>Safety and efficacy not evaluated in neonates<\/li><li><b>General guidelines:<\/b> Dose and duration dependent upon clinical condition and location and extent of bleeding; maximum single dose, 100 units\/kg; maximum daily dose, 200 units\/kg<\/li><li>Clinical response may not correlate with inhibitor titer; base on individual clinical response<\/li><li>Duration of therapy has extended to 72 hours; however, if bleeding is not controlled after 36 hours, treatment failure should be considered<\/li><li><b>Bleeding, Routine prophylaxis - Hereditary factor IX deficiency disease with inhibitor - Hereditary factor VIII deficiency disease with inhibitor:<\/b> 85 units\/kg IV every other day<\/li><li><b>Bleeding - Hereditary factor IX deficiency disease with inhibitor - Hereditary factor VIII deficiency disease with inhibitor:<\/b> Joint hemorrhage: 50 to 100 units\/kg IV every 12 hours until reduction in pain and in acute disability<\/li><li><b>Bleeding - Hereditary factor IX deficiency disease with inhibitor - Hereditary factor VIII deficiency disease with inhibitor:<\/b> Mucous membrane hemorrhage: 50 to 100 units\/kg IV every 6 hours for at least 1 day or until bleeding resolves<\/li><li><b>Bleeding - Hereditary factor IX deficiency disease with inhibitor - Hereditary factor VIII deficiency disease with inhibitor:<\/b> Soft tissue hemorrhage: 100 units\/kg IV every 12 hours until bleeding resolves<\/li><li><b>Bleeding - Hereditary factor IX deficiency disease with inhibitor - Hereditary factor VIII deficiency disease with inhibitor:<\/b> Severe hemorrhage (eg, CNS bleeding): 100 units\/kg IV every 6 to 12 hours until bleeding resolves<\/li><li><b>Bleeding - Hereditary factor IX deficiency disease with inhibitor - Hereditary factor VIII deficiency disease with inhibitor - Surgical procedure:<\/b> Preoperative dose: 50 to 100 units\/kg IV immediately before surgery<\/li><li><b>Bleeding - Hereditary factor IX deficiency disease with inhibitor - Hereditary factor VIII deficiency disease with inhibitor - Surgical procedure:<\/b> Postoperative dose: 50 to 100 units\/kg IV every 6 to 12 hours until bleeding resolves and healing is achieved<\/li><\/ul>"},"3":{"id":"qi6s1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Bleeding, Routine prophylaxis - Hereditary factor IX deficiency disease with inhibitor - Hereditary factor VIII deficiency disease with inhibitor<\/li><li>Bleeding - Hereditary factor IX deficiency disease with inhibitor - Hereditary factor VIII deficiency disease with inhibitor<\/li><li>Bleeding - Hereditary factor IX deficiency disease with inhibitor - Hereditary factor VIII deficiency disease with inhibitor - Surgical procedure<\/li><\/ul>"}}},"2":{"id":"qi6s2","title":"Black Box Warning","mono":"<b>Intravenous (Powder for Solution)<\/b><br\/>Thrombotic and thromboembolic events have been reported during post-marketing surveillance following infusion of anti-inhibitor coagulation complex, vapor heated (VH) or anti-inhibitor coagulation complex, nanofiltered (NF), particularly following the administration of high doses and\/or in patients with thrombotic risk factors.<br\/>"},"3":{"id":"qi6s3","title":"Contraindications\/Warnings","sub":[{"id":"qi6s3b9","title":"Contraindications","mono":"<ul><li>bleeding episodes resulting from coagulation factor deficiencies without inhibitors to coagulation factor VIII or IX<\/li><li>patients with normal coagulation mechanism<\/li><li>significant signs of disseminated intravascular coagulation (DIC)<\/li><\/ul>"},{"id":"qi6s3b10","title":"Precautions","mono":"<ul><li>thrombotic and thromboembolic events (DIC, venous thrombosis, pulmonary embolism, myocardial infraction, stroke) have been reported; especially following high doses and in patients with thrombotic risk factors<\/li><li>high dose; increased risk of thrombotic and thromboembolic events; monitoring recommended<\/li><li>patients with thrombotic risk factors (DIC or arterial or venous thrombosis, advanced atherosclerotic disease, crush injury, septicemia); increased risk of thrombotic and thromboembolic events<\/li><li>acute coronary ischemia, development of signs and symptoms; monitoring recommended<\/li><li>allergic reactions, including severe anaphylactoid reactions have been reported; discontinue therapy; may require medical management<\/li><li>concomitant use, within 12 hours of antifibrinolytics (tranexamic acid and aminocaproic acid); use not recommended<\/li><li>coronary heart disease, history; increased risk thromboembolic events<\/li><li>DIC, development of signs and symptoms; monitoring recommended; discontinue therapy; may require medical management<\/li><li>fibrinolytic patients; use not recommended<\/li><li>geriatric patients; increased risk thromboembolic events<\/li><li>human plasma derivative; infectious agent risk including viruses and theoretical risk of Creutzfeldt-Jakob disease<\/li><li>liver disease; increased risk thromboembolic events<\/li><li>neonates; increased risk thromboembolic events<\/li><li>nonhemophilic patients with acquired inhibitors to Factors VIII, IX, or XII; increased risk of bleeding and thrombosis<\/li><li>postoperative immobilized patients; increased risk thromboembolic events<\/li><li>rise in Factor VIII inhibitor titers have been reported, including increases 10-fold and greater<\/li><li>report all adverse events of infection to Baxter Healthcare 1-800-423-2862<\/li><\/ul>"},{"id":"qi6s3b11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"qi6s3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"qi6s4","title":"Drug Interactions","sub":{"1":{"id":"qi6s4b14","title":"Major","mono":"<ul><li>Aminocaproic Acid (theoretical)<\/li><li>Tranexamic Acid (theoretical)<\/li><\/ul>"}}},"5":{"id":"qi6s5","title":"Adverse Effects","mono":"<b>Common<\/b><br\/><b>Immunologic:<\/b>High antibody titer (20%)<br\/><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Myocardial infarction<\/li><li><b>Hematologic:<\/b>Disseminated intravascular coagulation, Thromboembolic disorder<\/li><li><b>Immunologic:<\/b>Anaphylactoid reaction<\/li><\/ul>"},"6":{"id":"qi6s6","title":"Drug Name Info","sub":{"0":{"id":"qi6s6b17","title":"US Trade Names","mono":"<ul><li>Autoplex T<\/li><li>Feiba-VH<\/li><li>Feiba NF<\/li><\/ul>"},"2":{"id":"qi6s6b19","title":"Class","mono":"Antihemophilic Agent<br\/>"},"3":{"id":"qi6s6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"qi6s6b21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"qi6s7","title":"Mechanism Of Action","mono":"Systemic: The exact mechanism of action of AICC is unknown, although it may be related to one or more of the active clotting factors and their ability to bypass the factor VIII inhibitor . In vitro experiments suggest the possibility of a factor Xa-like substance; or a complex of FVIIIC:Ag, factor IXa, and phospholipid as the active principle, which is only minimally inhibited by an inhibitor .<br\/>"},"9":{"id":"qi6s9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>Reconstitute using the provided need&le;ss transfer system and diluent; swirl gently to mix; do not shake.<\/li><li>Use within 3 hours of reconstitution; do not refrigerate.<\/li><li>Flush IV line with isotonic saline before and after administration; do not administer in same tubing or container as other medicine.<\/li><li>Use a plastic Luer syringe as FEIBA(TM) may stick to glass syringe.<\/li><li>Inject or infuse IV at a rate not to exceed 2 units\/kg\/minute.<\/li><\/ul>"},"10":{"id":"qi6s10","title":"Monitoring","mono":"<ul><li>blood indicators of disseminated intravascular coagulation (decreased fibrinogen, decreased platelet count, presence of fibrin-fibrinogen degradation products; prolonged thrombin time, prothrombin time, or partial thromboplastin time)<\/li><li>signs of intravascular coagulation (changes in blood pressure, pulse rate, respiratory distress, chest pain and cough)<\/li><li>signs of a thromboembolic event, particularly after high dosing<\/li><\/ul>"},"11":{"id":"qi6s11","title":"How Supplied","mono":"<ul><li><b>Feiba NF<\/b><br\/>Intravenous Powder for Solution: 1 IU<br\/><\/li><li><b>Feiba-VH<\/b><br\/>Intravenous Powder for Solution: 1 IU<br\/><\/li><\/ul>"},"13":{"id":"qi6s13","title":"Clinical Teaching","mono":"<ul><li>This drug may cause headache, flushing fever, or chills.<\/li><li>Instruct patient to report signs\/symptoms of a thromboembolic event or myocardial infarction.<\/li><\/ul>"}}}